Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143623 | 1.00 | CES2 (0.45) | CES2CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL2510406 | 1.00 | CES2 (0.45) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL3138536 | 0.98 | CYP2D6 (0.44) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL4175172 | 0.98 | CYP2D6 (0.44) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL4486187 | 0.98 | CYP2D6 (0.44) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Acetic Acid SCHEMBL4478409 | 0.95 | TACR1 (0.43) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Acetic Acid SCHEMBL4478690 | 0.95 | TACR1 (0.43) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Trifluoroacetic Acid SCHEMBL5163095 | 0.93 | TACR1 (0.42) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Trifluoroacetic Acid SCHEMBL5395810 | 0.93 | TACR1 (0.42) | CES2CYP2D6PSEN1PSEN2APH1B | |
| Sulfuric Acid SCHEMBL3142700 | 0.93 | CYP2D6 (0.41) | CES2CYP2D6PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113274392-A | Orvipitan for treating chronic cough | 尼尔医疗有限公司 | 2021-08-20 | — | — | CN | claimed |
| CN-108430475-B | Orvipitan for treating chronic cough | 尼尔医疗有限公司 | 2021-03-16 | — | — | CN | claimed |
| EP-2906219-B1 | ORVEPITANT FOR THE TREATMENT OF CHRONIC PRURITUS | NERRE THERAPEUTICS LTD (GB) | 2019-08-07 | — | — | EP | claimed |
| EP-3377064-B1 | ORVEPITANT FOR THE TREATMENT OF CHRONIC COUGH | NERRE THERAPEUTICS LTD (GB) | 2019-06-26 | — | — | EP | claimed |
| US-9907795-B2 | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | NERRE THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | claimed |
| US-20170326140-A1 | NOVEL USES | NERRE THERAPEUTICS LIMITED (GB) | 2017-11-16 | — | — | US | claimed |
| US-20170326141-A1 | METHOD OF TREATMENT OF CHRONIC COUGH ADMINISTERING ORVEPITANT IN COMBINATION WITH OTHER THERAPEUTIC AGENTS | NERRE THERAPEUTICS LIMITED (GB) | 2017-11-16 | — | — | US | claimed |
| US-9750739-B2 | Orvepitant for chronic cough therapy | NERRE THERAPEUTICS LIMITED (GB) | 2017-09-05 | — | — | US | claimed |
| US-20170196860-A1 | Novel Uses | NERRE THERAPEUTICS LIMITED (GB) | 2017-07-13 | — | — | US | claimed |
| US-9603849-B2 | Uses of orvepitant | NERRE THERAPEUTICS LIMITED (GB) | 2017-03-28 | — | — | US | claimed |
| EP-1218359-B1 | PIPERAZINE COMPOUNDS AS TACHYKININS ANTAGONISTS | GLAXO GROUP LTD (GB) | 2004-07-07 | — | — | EP | claimed |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-07-01 | — | — | US | claimed |
| US-20040048862-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-03-11 | — | — | US | claimed |
| US-20040014770-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | US | claimed |
| US-6642240-B2 | Piperazine derivatives; antagonists of tachykinins, including substance P; 2-(4-fluoro-2-methyl-phenyl)piperazine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)methyl amide for example | SMITHKLINE BEECHAM CORPORATION | 2003-11-04 | — | — | US | claimed |
| EP-1326832-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-07-16 | — | — | EP | claimed |
| US-20030028021-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2003-02-06 | — | — | US | claimed |
| EP-1218359-A2 | PIPERAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-07-03 | — | — | EP | claimed |
| WO-2002032867-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | claimed |
| WO-2001025219-A2 | PIPERAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326140-A1 | NOVEL USES | TPMT, MPST, COLGALT1 | CES2 3912/4885CYP2D6 2519/4885PSEN1 2181/4885 |
| US-20030028021-A1 | Chemical compounds | TACR1, TACR2, TAC3 | CES2 1790/4885CYP2D6 1698/4885PSEN1 1241/4885 |
| US-20170326141-A1 | METHOD OF TREATMENT OF CHRONIC COUGH ADMINISTERING ORVEPITANT IN COMBINATION WITH OTHER THERAPEUTIC AGENTS | OPRD1, OPRK1, OPRM1 | CES2 1625/4885CYP2D6 664/4885PSEN1 4108/4885 |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | NPY1R, CRHR1, GRIN1 | CES2 2321/4885CYP2D6 472/4885PSEN1 2253/4885 |
| US-20040048862-A1 | Chemical compounds | TACR1, TACR2, TAC3 | CES2 1790/4885CYP2D6 1698/4885PSEN1 1241/4885 |
| US-20040014770-A1 | Chemical compounds | HCK, KCNK4, GRK4 | CES2 1424/4885CYP2D6 478/4885PSEN1 3789/4885 |
| US-20170196860-A1 | Novel Uses | OPRD1, OPRM1, OPRK1 | CES2 1364/4885CYP2D6 1511/4885PSEN1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.